ArticleAmerican journal of translational research2017
The injection of DisCoVisc into the anterior chamber improved corneal preservation and transplantation for cornea blind patients.
Article in American journal of translational research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Transient vacuolar changes of the crystalline lens in patients using a dispersive ophthalmic viscosurgical device.International journal of ophthalmology · 2023Article
- Thickness of the Protective Layers of Different Ophthalmic Viscosurgical Devices During Lens Surgery in a Porcine Model.Translational vision science & technology · 2022Article
- S1P promotes corneal trigeminal neuron differentiation and corneal nerve repair via upregulating nerve growth factor expression in a mouse model.Open life sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIn this study, we aimed to provide a new method of corneal preservation by injecting DisCoVisc into the anterior chamber of eyeballs and evaluate its efficiency for corneal transplantation.
methodsThree pairs of eyeballs (n=6) were preserved by DisCoVisc viscoelastic agent, and the corneas were stored for 1 to 6 days. Then, the structure and morphology of cornea were analyzed by hematoxylin-eosin (H&E) staining, terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining, and transmission electron microscopy (TEM). The corneas preserved by this method were transplanted into 15 patients with corneal disease and the efficacy was assessed.
resultsEpithelial cells and endothelial cells were intact and a normal morphology was preserved in both fresh corneas and corneas stored for 1-6 days by DisCoVisc viscoelastic agent. Corneal endothelial cells did not appear apoptosis in fresh corneas and corneas stored for 1-3 days, whereas a few apoptosis positive cells were shown on the 4
conclusionsCorneal preservation technology with the injection of DisCoVisc viscoelastic agent may effectively extend the preservation time of corneas for five days, which could be used for patients as penetrating keratoplasty surgery.
Indexed as
Identifiers
28979685PMC5622254What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.